Cannabis & Multiple Sclerosis: What the Research Shows

Multiple sclerosis (MS) is a chronic neuroinflammatory disease affecting approximately 1 million Americans and 2.8 million people worldwide. Its signature symptoms — spasticity, pain, bladder dysfunction, fatigue, and difficulty walking — are often poorly controlled by standard disease-modifying therapies, and it is precisely in this symptom management gap that cannabinoid research has found its most clinically validated application.

Cannabis use among MS patients is among the highest of any medical population: surveys consistently find 20–30% of MS patients report using cannabis for symptom relief, creating both a public health imperative to understand the evidence and an ethical obligation to provide honest clinical guidance.

What the Research Shows

The Cannabis in Multiple Sclerosis (CAMS) study by Zajicek et al., published in The Lancet in 2003, remains the largest cannabis trial in MS and one of the largest cannabinoid trials ever conducted [1]. This 12-month, double-blind, placebo-controlled trial enrolled 667 patients with MS-related spasticity across 33 UK centers. Patients received oral THC (dronabinol), whole-plant cannabis extract (a 1:1 THC:CBD oral spray), or placebo. While the primary endpoint — objective spasticity measured by the Ashworth scale — did not reach statistical significance, a key secondary finding changed the field: subjectively reported spasticity, pain, and sleep quality improved significantly in both active treatment groups. Patient-reported outcomes showed a 30–40% improvement in these quality-of-life measures. The disconnect between objective and subjective measurement has generated ongoing debate about which endpoint truly reflects therapeutic benefit.

A subsequent study by Collin et al. (2007) in the European Journal of Neurology specifically examined Sativex — the 1:1 THC:CBD oromucosal spray — in MS spasticity using a patient self-assessment scale as the primary outcome [2]. This trial randomised 189 patients (184 in the intention-to-treat analysis) and found the active preparation significantly superior on the primary spasticity measure (p=0.048); in the responder analysis, 40% of subjects achieved greater than 30% benefit (p=0.014). In 2010, the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved Sativex for MS-related spasticity in patients who had not responded adequately to other treatments — making it the first cannabis-based prescription medicine approved in a major Western jurisdiction [3].

Beyond spasticity, neuropathic pain in MS has been examined in several controlled trials. Cannabis-based medicines consistently outperform placebo for central neuropathic pain in MS, with effect sizes suggesting cannabis is at least as effective as standard neuropathic pain agents. Bladder dysfunction — another significant MS symptom — showed modest improvement in cannabis-treated patients in the CAMS long-term follow-up data.

Key Findings

Expert Perspective

"What was striking about the CAMS data was the consistency between patient self-report and the objective data being discordant. These were patients with established, difficult-to-treat MS who were telling us their spasticity felt better — and we know subjective spasticity is what determines quality of life. That led directly to the recommendation that patient-reported outcomes should be primary endpoints in cannabis trials for chronic symptom management."

— Professor John Zajicek, lead author of the CAMS trial, Peninsula College of Medicine and Dentistry

What This Means for Patients

MS patients have more high-quality evidence supporting cannabis use than almost any other patient population, and uniquely, an approved pharmaceutical product (Sativex/nabiximols) exists in many countries specifically for their indication. In the United States, Sativex is not yet FDA-approved but is available in many legal states through the medical cannabis system.

The evidence most strongly supports cannabinoid treatment for MS-related spasticity and central neuropathic pain. For patients who have tried standard spasticity medications (baclofen, tizanidine, diazepam) with inadequate results or intolerable side effects, cannabis-based medicines represent a validated next step in many evidence-based treatment guidelines outside the U.S.

As with all cannabis treatments, delivery method matters significantly: the oromucosal spray used in Sativex provides more precise dosing and faster titration than oral cannabis preparations, and is the form with the strongest evidence base for MS specifically.